참고문헌 (35)

1. J Hypertens PM Kearney 22 11 2004 10.1097/00004872-200401000-00003 Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11-9. 

   상세보기

2. 10.1097/01.hjh.0000431740.32696.cc Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force M. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357 

   상세보기

3. Curr Hypertens Rep JB Cowart 14 324 2012 10.1007/s11906-012-0280-9 Cowart JB, Taylor AA. Should two-drug initial therapy for hypertension be recommended for all patients? Curr Hypertens Rep. 2012;14:324-32. 

   상세보기

4. 10.1177/2047487312450228 Fifth Joint Task Force of the European Society of C, European Association of E, European Association of Percutaneous Cardiovascular I, European Heart Rhythm A, Heart Failure A, European Association for Cardiovascular P, Rehabilitation, European Atherosclerosis S, International Society of Behavioural M, European Stroke O, European Society of H, European Association for the Study of D, European Society of General Practice/Family M, International Diabetes Federation E, European Heart N. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19:585-667. 

   상세보기

5. Vasc Health Risk Manag E Pimenta 4 653 2008 10.2147/VHRM.S2586 Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag. 2008;4:653-64. 

   

6. Blood Press SE Kjeldsen 17 7 2008 10.1080/08037050801972857 Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlof B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M. Avoiding cardiovascular events through CtiPLwSHI: predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the Accomplish Study. Blood Press. 2008;17:7-17. 

   상세보기

7. J Clin Hypertens H Geiger 11 324 2009 10.1111/j.1751-7176.2009.00114.x Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, Zhang J. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens. 2009;11:324-32. 

   상세보기

8. Congest Heart Fail AA Taylor 9 324 2003 10.1111/j.1527-5299.2003.03269.x Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril hcl versus comparable component-based therapy. Congest Heart Fail. 2003;9:324-32. 

   상세보기

9. J Clin Hypertens SG Chrysant 11 475 2009 10.1111/j.1751-7176.2009.00159.x Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens. 2009;11:475-82. 

   상세보기

10. J Clin Hypertens JL Izzo Jr 13 873 2011 10.1111/j.1751-7176.2011.00544.x Izzo JL Jr, Chrysant SG, Kereiakes DJ, Littlejohn Iii T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the Trinity Ambulatory Blood Pressure Substudy. J Clin Hypertens. 2011;13:873-80. 

    상세보기

11. J Clin Hypertens DJ Kereiakes 14 149 2012 10.1111/j.1751-7176.2011.00588.x Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens. 2012;14:149-57. 

    상세보기

12. J Hum Hypertens S Oparil 24 831 2010 10.1038/jhh.2010.16 Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the coach trial. J Hum Hypertens. 2010;24:831-8. 

    상세보기

13. Clin Ther S Oparil 32 1252 2010 10.1016/j.clinthera.2010.07.008 Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the trinity multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252-69. 

    상세보기

14. J Clin Hypertens DE Morisky 10 348 2008 10.1111/j.1751-7176.2008.07572.x Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10:348-54. 

    상세보기

15. Am J Manage Care M Krousel-Wood 15 59 2009 Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manage Care. 2009;15:59-66. 

16. J Manage Care Pharm TJ Bramley 12 239 2006 10.18553/jmcp.2006.12.3.239 Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manage Care Pharm. 2006;12:239-45. 

    

17. JAMA JK Lee 296 2563 2006 10.1001/jama.296.21.joc60162 Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-71. 

    상세보기

18. J Clin Hypertens MN Hill 12 757 2010 10.1111/j.1751-7176.2010.00356.x Hill MN, Miller NH, DeGeest S, American Society of Hypertension Writing Group. Ash position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens. 2010;12:757-64. 

    상세보기

19. Hypertension M Krousel-Wood 58 804 2011 10.1161/HYPERTENSIONAHA.111.176859 Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS, Morisky DE, Frohlich ED, Re RN. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58:804-10. 

    상세보기

20. J Hypertens G Corrao 29 610 2011 10.1097/HJH.0b013e328342ca97 Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610-8. 

    상세보기

21. Circulation G Mazzaglia 120 1598 2009 10.1161/CIRCULATIONAHA.108.830299 Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-605. 

    상세보기

22. Ther Adv Cardiovasc Dis CM Ferrario 7 27 2013 10.1177/1753944712470979 Ferrario CM, Panjabi S, Buzinec P, Swindle JP. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis. 2013;7:27-39. 

    상세보기

23. J Intern Med S Perreault 266 207 2009 10.1111/j.1365-2796.2009.02084.x Perreault S, Dragomir A, White M, Lalonde L, Blais L, Berard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207-18. 

    상세보기

24. Br J Clin Pharmacol S Perreault 69 74 2010 10.1111/j.1365-2125.2009.03547.x Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L, Berard A. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69:74-84. 

    상세보기

25. Stroke J Cereb Circ FZ Kettani 40 213 2009 10.1161/STROKEAHA.108.522193 Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, Blais L, Lalonde L, Moreau P, Perreault S. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke J Cereb Circ. 2009;40:213-20. 

    상세보기

26. J Hum Hypertens JC Prado Jr 21 579 2007 10.1038/sj.jhh.1002196 Prado JC Jr, Kupek E, Mion D Jr. Validity of four indirect methods to measure adherence in primary care hypertensives. J Hum Hypertens. 2007;21:579-84. 

    상세보기

27. Cardiovasc Diabetol P Bramlage 8 18 2009 10.1186/1475-2840-8-18 Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment: a review. Cardiovasc Diabetol. 2009;8:18. 

    상세보기

28. Health Technol Assess M Law 7 1 2003 10.3310/hta7010 Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7:1-94. 

    상세보기

29. J Clin Hypertens LD Esposti 6 76 2004 10.1111/j.1524-6175.2004.03044.x Esposti LD, Di Martino M, Saragoni S, Sgreccia A, Capone A, Buda S, Esposti ED. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens. 2004;6:76-84. 

    상세보기

30. Eur J Clin Pharmacol J Hasford 63 1055 2007 10.1007/s00228-007-0340-2 Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63:1055-61. 

    상세보기

31. J Clin Hypertens BV Patel 9 692 2007 10.1111/j.1524-6175.2007.07194.x Patel BV, Remigio-Baker RA, Mehta D, Thiebaud P, Frech-Tamas F, Preblick R. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens. 2007;9:692-700. 

    상세보기

32. Pharmacoepidemiol Drug Saf JA Erkens 14 795 2005 10.1002/pds.1156 Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a pharmo study. Pharmacoepidemiol Drug Saf. 2005;14:795-803. 

    상세보기

33. Vasc Health Risk Manag M Veronesi 3 999 2007 Veronesi M, Cicero AF, Prandin MG, Dormi A, Cosentino E, Strocchi E, Borghi C. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3:999-1005. 

34. Clin Ther BS Bloom 20 671 1998 10.1016/S0149-2918(98)80130-6 Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-81. 

    상세보기

35. Expert Opin Pharmacother G Tocci 13 2687 2012 10.1517/14656566.2012.745510 Tocci G, Paneni F, Passerini J, Volpe M. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy. Expert Opin Pharmacother. 2012;13:2687-97. 

    상세보기